GlassScriptPhysician profile
Gregory Frederick Dimesa
NPI 1568994275
$2,234.75
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $188 · 2021: $567 · 2022: $422 · 2023: $592 · 2024: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $643.68 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $301.44 | 2020-2023 | Steglatro, Segluromet |
| Novo Nordisk INC | $275.13 | 2021-2024 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $206.15 | 2022-2024 | Sunosi |
| Daiichi Sankyo INC. | $199.69 | 2021-2024 | Injectafer |
| Abbvie INC. | $182.02 | 2021-2024 | Ubrelvy, Qulipta |
| Exact Sciences Corporation | $156.29 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.81 | 2020-2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $41.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.48 | 2021-2022 | |
| Genentech USA, INC. | $27.82 | 2020 | |
| Jazz Pharmaceuticals INC. | $24.70 | 2021-2022 | |
| Boston Scientific Corporation | $17.53 | 2023 | Watchman Flx |
| Scynexis, INC. | $16.66 | 2022 | |
| Lilly USA, LLC | $15.88 | 2024 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Dimesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.